EA021967B1 - Доставка антител посредством модульного домена распознавания - Google Patents
Доставка антител посредством модульного домена распознавания Download PDFInfo
- Publication number
- EA021967B1 EA021967B1 EA201070822A EA201070822A EA021967B1 EA 021967 B1 EA021967 B1 EA 021967B1 EA 201070822 A EA201070822 A EA 201070822A EA 201070822 A EA201070822 A EA 201070822A EA 021967 B1 EA021967 B1 EA 021967B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fusion polypeptide
- μκό
- antibody
- zeo
- polypeptide according
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 17
- 230000004927 fusion Effects 0.000 claims 15
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 101000996032 Xenopus laevis Nodal homolog Proteins 0.000 claims 1
- 101150060298 add2 gene Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Mycology (AREA)
Abstract
В настоящем изобретении описаны антитела, содержащие один или несколько модульных доменов распознавания (MRD), используемых для доставки антител в конкретные участки. В настоящем изобретении также описано применение антител, содержащих один или несколько модульных доменов распознавания, для лечения заболеваний и описаны способы получения антител, содержащих один или несколько модульных доменов распознавания.
Description
В общих чертах настоящее изобретение относится к антителам, содержащим один или более модульных доменов распознавания, а более конкретно к применению антител, содержащих один или более указанных модульных доменов распознавания, для лечения заболеваний и к способам получения антител, содержащих один или более указанных модульных доменов распознавания.
Предшествующий уровень техники
Каталитически активные моноклональные антитела (АЬ) могут быть использованы для селективной активации пролекарств и химических превращений. Моноклональные антитела АЬ, обладающие альдолазной активностью, действуют как высокоэффективные катализаторы для ряда химических превращений, в частности в альдольных и ретроальдольных реакциях. Ретроальдолазная активность антител АЬ, таких как 38С2 и 93Р3, дает возможность исследователям конструировать, синтезировать и оценивать пролекарства различных химиотерапевтических средств, которые могут активироваться посредством ретроальдольных реакций (конструирование 38С2 описано в заявке \УО 97/21803, которая вводится в настоящее описание посредством ссылки). 38С2 содержит антигенсвязывающий сайт, который катализирует реакцию альдольной конденсации между алифатическим донором и альдегидным акцептором. У сингенных мышей с моделью нейробластомы системное введение пролекарства этопозида и внутриопухолевая инъекция 38С2 приводили к ингибированию роста опухоли.
Одним из недостатков применения каталитических АЬ является отсутствие средства для доставки каталитического АЬ в злокачественные клетки. Предварительные исследования показали, что в способе проведения антителозависимой опосредуемой ферментом пролекарственной терапии (АОЕРТ) или антителозависимой опосредуемой абзимом пролекарственной терапии (АОАРТ) ферменты или каталитические антитела могут быть доставлены в опухолевые клетки посредством химического конъюгирования или рекомбинантного присоединения к антителам, предназначенным для доставки. Однако в качестве более эффективной альтернативы может быть использовано каталитическое антитело, присоединенное к пептиду, предназначенному для доставки и расположенному за пределами антигенсвязывающего сайта, что делает активный центр доступным для активации пролекарства. Так, например, присоединение АЬ 38С2 к пептиду, связывающемуся с интегрином ανβ3, позволяет антителу селективно локализоваться в опухоли и/или в сосудистой сети опухоли и запускать активацию пролекарства в этой области. Возможность осуществления такого способа терапии была подтверждена данными преклинических и клинических исследований фазы III и дает основание предположить, что пептиды могут быть превращены в полноценные лекарственные средства посредством их присоединения к Ре-областям антитела.
Получение биспецифических или мультиспецифических антител, которые могут доставляться одновременно в две или более раковые опухоли-мишени и/или активировать пролекарства, представляет собой новый и перспективный способ лечения раковых и других заболеваний. Такие антитела проиллюстрированы на фиг. 1 настоящего изобретения. Исследования биспецифических антител (ВкАЬ), одновременно нацеленных на два опухолеассоциированных антигена (например, на рецепторы фактора роста), которые проводились для оценки ингибирования путей пролиферации/выживания множества клеток, подтвердили эффективность данного способа. Обычно биспецифические антитела получают путем химического связывания двух различных моноклональных антител или путем слияния двух гибридомных клеточных линий с продуцированием гибридомы-гибрида. Биспецифические четырехвалентные 1§Оподобные молекулы или иммуноглобулины, состоящие из двух вариабельных доменов, были сконструированы из двух моноклональных антител. Эти иммуноглобулины, состоящие из двух вариабельных доменов, обладают способностью связываться с обоими антигенами в присутствии сыворотки. Однако такие способы имеют определенные недостатки с точки зрения их промышленного получения, выхода и чистоты.
Claims (19)
1. Выделенный слитый полипептид для направленной доставки антитела к опухоли, содержащий полноразмерное антитело и по меньшей мере один модульный домен распознавания (ΜΚΌ), где указанное антитело способно связываться с опухолевым антигеном, а указанный ΜΚΌ способен связываться с ангиогенным фактором и где ΜΚΌ состоит из 2-60 аминокислот.
2. Слитый полипептид по п.1, где указанное антитело и указанный ΜΚΌ функционально связаны посредством линкерного пептида.
3. Слитый полипептид по п.2, где указанный линкерный пептид состоит из 2-20 аминокислот или 415 аминокислот.
4. Слитый полипептид по п.2 или 3, где указанный линкерный пептид содержит последовательность, выбранную из группы, состоящей из:
СССЗ (5Е<2 Ιϋ N0:1),
ЗЗССОСЗОСООССЗЗ (ЗЕО Ю N0:2) и
ЗЗССССЗССССССЗЗЕЗЗ (ЗЕО Ιϋ N0:19).
5. Слитый полипептид по любому из пп.1-4, где указанный ΜΚΌ функционально связан с С-концом тяжелой цепи указанного антитела, с ^концом тяжелой цепи указанного антитела, с С-концом легкой
- 41 021967 цепи указанного антитела или с Ν-концом легкой цепи указанного антитела.
6. Слитый полипептид по любому из пп.1-5, где два или более ΜΚΌ функционально связаны с любым концом указанного антитела или где два или более ΜΚΌ функционально связаны с двумя или более концами указанного антитела.
7. Слитый полипептид по любому из пп.1-6, где указанный ангиогенный фактор выбран из группы, состоящей из ангиогенного цитокина, васкулярного эндотелиального фактора роста (УЕ0Р) и васкулярного хоминг-пептида.
8. Слитый полипептид по п.7, где указанный ангиогенный фактор представляет собой ангиогенный цитокин, а указанный ΜΚΌ содержит последовательность, выбранную из группы, состоящей из:
МСАОТЫРМРМЦОЬЕОКЬУЕОРШОООЬЕ (ЗЕ<2 Ю N0:7),
МСАОТЫРМРМОЫЦЕЬШУЕОРШООСЬЕ {ЗЕ<2 ТО N0:8),
МОАОТНРМРМЦАТЕТЕЬУЕОРШООСЬЕ {ЗЕО ТО N0:9),
А00ЕЕСЕТОРНТСЕНМС5С5АТСС8С5ТАЗ3СЗСЗАТНОЕЕ СЕНОРИТСЕНМЬЕ АООЕЕСЕРАРНТСЕНМ (ЗЕО ТО N0:21),
АООЕЕСЕРАРНТСЕНМСЗОЗАТОеЗСЗТАЗЗСЗСЗАТНОЕЕСЕРАРНТСЕНМОЕ АООЕЕСЕЬАРНТСЕНМ {ЗЕО ТО N0:24),
АООЕЕСЕЬАРНТСЕНМСЗОЗАТСОЗСЗТАЗЗСЗСЗАТНОЕЕСЕЬАРНТСЕНМЬЕ АООЕЕСЕРЗРНТСЕНМ {ЗЕО ТО N0:27),
АООЕЕСЕРЗРНТСЕНМСЗСЗАТССЗСЗТАЗЗОЗСЗАТНОЕЕСЕРЗРНТСЕНМЬЕ АООЕЕСЕЬЕРНТСЕНМ (ЗЕ<2 ТО N0:30),
АООЕЕСЕЬЕРНТСЕНМСЗСЗАТОСЗСЗТАЗЗСЗСЗАТНОЕЕСЕЬЕРНТСЕНМЬЕ АООЕЕСЕРАРНТСЕНМСЗСЗАТССЗСЗТАЗЗОЗСЗАТНОЕЕСЕЬАРНТСЕНМЬЕ АООЕЕ СЕРАРНТСЕНМСЗСЗАТСОЗСЗ ТАЗ ЗСЗСЗ ΑΤΗζ)ΕΕ СЕРЗ РИТСЕНМЬЕ ΜΘΑΟΤΝΡΜΡΜΟΝΟΕΕΒΝΥΕΟΡΙΏΟΟΘΒΕ (3ΕΏ 10 N0:11) И
РХОИОХЬЬИУ (ЗЕ<2 ТО N0:12), (5Е0 ТО N0:10), (ЗЕО ТО N0:23), {ЗЕО ТО N0:26),
2ХСОПРЗ (ЗЕ<2 ТО N0:29), (ЗЕО ТО N0:32), (ЗЕ<2 10 N0:33) , {ЗЕО ТО N0:34), где X выбран из 20 природных аминокислот;
указанный ангиогенный фактор представляет собой УЕ0Р, а указанный ΜΚΌ содержит последовательность УЕРИСЩНУМНЕНЕСРЕКЬ (3Εζ) ТО N0:13) или указанный ангиогенный фактор представляет собой васкулярный хоминг-пептид, а указанный ΜΚΌ содержит последовательность АСЕ>СКСЕ>СГСС (3Εζ) то N0:15).
9. Слитый полипептид по любому из пп.1-8, где указанное антитело представляет собой химерное или гуманизированное антитело.
10. Слитый полипептид по любому из пп.1-9, где указанное антитело связывается с ЕгЬВ2.
11. Слитый полипептид по п.10, где указанное антитело представляет собой трастузумаб.
12. Слитый полипептид по любому из пп.1-11, где указанный ангиогенный фактор, являющийся мишенью для ΜΚΌ, представляет собой Апд2.
13. Слитый полипептид по п.12, где указанный ΜΚΌ содержит 8ЕР ΙΌ Ν0:8.
14. Слитый полипептид по любому из пп.1-7 и 9-12, где указанный ΜΚΌ содержит последовательность, выбранную из группы, состоящей из:
МОАОТЫРМРМОНПЕЬЬЬУЕОРХЬСООЬЕООЙСЗТАЗЗОЗОЗЗЬСАОТНРМРМОГГОЕЬЬЬУ {3Εζ2ΙΌ N0:20);
ХпРИЛШУТХп, где п составляет примерно 0-50 аминокислотных остатков (8РО ΙΌ Ν0:22);
ΧιιΡΙ,ΆΡ\ΥΤΧιι, где п составляет примерно 0-50 аминокислотных остатков (8ЕР ΙΌ Ν0:25); ΧιιΡΙ;8Ρ\\'ΤΧιι, где п составляет примерно 0-50 аминокислотных остатков (8ЕР ΙΌ Ν0:28);
ХпР1 .РШУТХп, где п составляет примерно 0-50 аминокислотных остатков (8ЕР ΙΌ Ν0:31); XηА^^ЕЕСЕX1X2Ρ^ТСЕНΜXη, где п составляет примерно 0-50 аминокислотных остатков, а X,
Х1 и Х2 представляют собой любую аминокислоту (8ЕР ΙΌ Ν0:57);
- 42 021967
АООЕЕСЕРАРМТСЕНМ (ЗЕО ГО N0:21) ;
АООЕЕСЕРАРИТСЕНМСЗОЗАТаСЗСЗТАЗЗСЗСЗАТНОЕЕСЕГАРМТСЕНМЬЕ (ЗЕО ГО N0:23); АОСЕЕСЕЬАРМТСЕНМ (ЗЕО ГО N0:24);
АООЕЕСЕЬАРИТСЕНМСЗСЗАТСОЗСЗТАЗЗСЗОЗАТНОЕЕСЕЪАРМТСЕНМЬЕ (5Е<2 ГО N0:26); АООЕЕСЕЕЗРМТСЕНМ (8Е<2 ГО N0:27) ;
АООЕЕСЕГЗРИТСЕНМСЗСЗАТССЗСЗТАЗЗСЗСЗАТНОЕЕСЕРЗРИТСЕНМЬЕ 2ХСОПР5 (ЗЕО 10 N0:29); АООЕЕСЕЬЕРМТСЕНМ (5Е<2 ГО N0:30);
АООЕЕСЕЬЕРМТСЕНМСЗеЗАТССЗаЗТАЗЗСЗСЗАТНОЕЕСЕЪЕРМТСЕНМЬЕ (ЗЕО ГО N0:32); АООЕЕСЕРАРМТСЕНМСЗСЗАТООЗСЗТАЗЗСЗСЗАТНОЕЕСЕЪАРМТСЕНМЬЕ (5Е<2 ГО N0:33); АООЕЕСЕРАРМТСЕНМСЗСЗАТССЗСЗТАЗЗСЗСЗАТНОЕЕСЕРБРИТСЕНМЬЕ (ЗЕ<2 ГО N0:34) и АООЕЕСЕИОРНТСЕНМСЗСЗАТССЗСЗТАЗЗСЗОЗАТНОЕЕСЕИОРМТСЕНМЬЕ (ЗЕО ГО N0:10).
15. Выделенный полинуклеотид, содержащий нуклеотидную последовательность, кодирующую слитый полипептид по любому из пп.1-14.
16. Вектор, содержащий полинуклеотид по п.15.
17. Клетка-хозяин, содержащая вектор по п.16, или потомство указанной клетки.
18. Способ лечения рака, включающий введение индивидууму, нуждающемуся в этом, слитого полипептида по любому из пп.1-14.
19. Способ по п.18, где указанный слитый полипептид ингибирует ангиогенез, модулирует ангиогенез или ингибирует рост опухоли.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1881608P | 2008-01-03 | 2008-01-03 | |
US2276708P | 2008-01-22 | 2008-01-22 | |
PCT/US2008/088337 WO2009088805A2 (en) | 2008-01-03 | 2008-12-24 | Antibody targeting through a modular recognition domain |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201070822A1 EA201070822A1 (ru) | 2011-02-28 |
EA021967B1 true EA021967B1 (ru) | 2015-10-30 |
Family
ID=40853673
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500156A EA201500156A3 (ru) | 2008-01-03 | 2008-12-24 | Доставка антител посредством модульного домена распознавания |
EA201070822A EA021967B1 (ru) | 2008-01-03 | 2008-12-24 | Доставка антител посредством модульного домена распознавания |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500156A EA201500156A3 (ru) | 2008-01-03 | 2008-12-24 | Доставка антител посредством модульного домена распознавания |
Country Status (18)
Country | Link |
---|---|
US (3) | US20110189206A1 (ru) |
EP (2) | EP2769991B1 (ru) |
JP (3) | JP5774851B2 (ru) |
KR (1) | KR101658247B1 (ru) |
CN (3) | CN101965406A (ru) |
AU (1) | AU2008346734A1 (ru) |
BR (1) | BRPI0821906B1 (ru) |
CA (1) | CA2711256C (ru) |
DK (1) | DK2769991T3 (ru) |
EA (2) | EA201500156A3 (ru) |
ES (1) | ES2689274T3 (ru) |
GE (1) | GEP20156390B (ru) |
IL (3) | IL206602A0 (ru) |
MX (1) | MX2010007357A (ru) |
NZ (1) | NZ586701A (ru) |
SG (2) | SG189769A1 (ru) |
WO (1) | WO2009088805A2 (ru) |
ZA (1) | ZA201004730B (ru) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2711256C (en) | 2008-01-03 | 2019-01-15 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US8557242B2 (en) * | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8574577B2 (en) * | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557243B2 (en) * | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
JP2013506435A (ja) * | 2009-10-05 | 2013-02-28 | オプソニック セラピューティクス インコーポレイテッド | 抗体特異性をリダイレクトするための高親和性アダプター分子 |
WO2012007896A1 (en) | 2010-07-12 | 2012-01-19 | Covx Technologies Ireland, Ltd. | Multifunctional antibody conjugates |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
EP2646468B1 (en) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
WO2012109624A2 (en) * | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
AU2013295848B2 (en) | 2012-07-25 | 2018-05-24 | Celldex Therapeutics, Inc. | Anti-KIT antibodies and uses thereof |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
GB201308745D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
JP6391676B2 (ja) * | 2013-05-23 | 2018-09-19 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションAjou University Industry−Academic Cooperation Foundation | ニューロピリンに特異的な腫瘍浸透性ペプチド及びこのペプチドが融合された融合タンパク質 |
CA2931356A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
EP3087185A4 (en) | 2013-12-23 | 2017-09-06 | Zymeworks Inc. | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
EP3339320A4 (en) | 2015-08-17 | 2019-01-23 | Seoul National University R&DB Foundation | CHIMERIC ANTIBODY RECEPTOR WITH AN ANTI-COTININ ANTIBODY BELARED AND USE THEREOF |
MA43372A (fr) | 2015-12-04 | 2018-10-10 | Novartis Ag | Compositions à greffe de cytokine-anticorps et procédés d'utilisation pour l'immunorégulation |
BR112018074275A2 (pt) | 2016-05-27 | 2019-10-01 | Orum Therapeutics Inc | anticorpo de penetração no citosol e método de produção do mesmo |
EP3496742A4 (en) | 2016-12-01 | 2020-04-08 | University Of South Florida | PEPTICORPS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING EAR FIBRILLATION |
JP7033601B2 (ja) | 2017-01-05 | 2022-03-10 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 |
TWI788321B (zh) * | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
KR20200010468A (ko) | 2017-05-24 | 2020-01-30 | 노파르티스 아게 | 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2019013140A1 (ja) | 2017-07-14 | 2019-01-17 | 三井化学株式会社 | フルオロリン酸ホウ素リチウム錯化合物、フルオロリン酸ホウ素リチウム含有組成物、フルオロリン酸ホウ素リチウム、リチウム二次電池用添加剤、電池用非水電解液、及びリチウム二次電池 |
CN112313333A (zh) | 2018-05-10 | 2021-02-02 | 秘来生物制剂株式会社 | 包含抗体的抗原结合区、融合生理活性肽的人工蛋白质 |
KR20190143826A (ko) | 2018-06-21 | 2019-12-31 | 오름테라퓨틱 주식회사 | 세포/조직 특이적 세포 침투 항체 |
CN113329769A (zh) * | 2018-10-11 | 2021-08-31 | 斯克里普斯研究学院 | 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物 |
JP7317343B2 (ja) * | 2019-03-20 | 2023-07-31 | 公立大学法人大阪 | 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030229023A1 (en) * | 2001-10-11 | 2003-12-11 | Oliner Jonathan Daniel | Specific binding agents of human angiopoietin-2 |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20060128944A1 (en) * | 2001-08-21 | 2006-06-15 | Yeda Research And Development Co. Ltd. At The Weizmann Instritute Of Science | Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors |
US20070202041A1 (en) * | 2006-02-24 | 2007-08-30 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US20070254316A1 (en) * | 2002-08-05 | 2007-11-01 | Johns Hopkins University | Peptides for targeting the prostate specific membrane antigen |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5196193A (en) * | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
LU91067I2 (fr) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6025165A (en) | 1991-11-25 | 2000-02-15 | Enzon, Inc. | Methods for producing multivalent antigen-binding proteins |
US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
CA2145278C (en) | 1992-09-25 | 2009-03-10 | Peter J. Hudson | Target binding polypeptide |
US6733752B1 (en) | 1994-03-30 | 2004-05-11 | The Trustees Of The University Of Pennsylvania | Prevention of tumors with monoclonal antibodies against neu |
DE69527050T2 (de) | 1994-03-07 | 2003-02-13 | Medarex Inc | Bispezifische moleküle mit klinischer verwendbarkeit |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US7063840B2 (en) | 1994-10-07 | 2006-06-20 | Regeneron Pharmaceuticals, Inc. | TIE-2 ligands, methods of making and uses thereof |
AU6113396A (en) | 1995-06-14 | 1997-01-15 | Regents Of The University Of California, The | Novel high affinity human antibodies to tumor antigens |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
CN100360184C (zh) | 1995-07-27 | 2008-01-09 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6489447B1 (en) | 1998-05-06 | 2002-12-03 | Genentech, Inc. | Protein purification |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
HU229038B1 (hu) * | 1998-09-14 | 2013-07-29 | Regents Board Of | A mielóma multiplex és a mielóma indukált csontreszorpció kezelése integrin antagonistákkal |
MXPA01008110A (es) | 1999-02-12 | 2002-10-23 | Scripps Research Inst | Metodos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias anti-angiogenicas e inmunoterapia. |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
AU783960B2 (en) | 1999-06-07 | 2006-01-05 | Immunex Corporation | Tek antagonists |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
CA2383493C (en) | 1999-06-25 | 2010-08-10 | Genentech, Inc. | Treating prostate cancer with anti-erbb2 antibodies |
CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
EP2111870A1 (en) | 1999-08-27 | 2009-10-28 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
US6497909B1 (en) | 1999-09-09 | 2002-12-24 | General Mills, Inc. | Method of bleaching cereal grain |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
WO2001081377A2 (en) | 2000-04-21 | 2001-11-01 | Amgen, Inc. | Integrin/adhesion antagonists |
AU6469601A (en) | 2000-05-19 | 2001-12-03 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to anerbb antagonist cancer therapy |
CN100335132C (zh) * | 2001-01-09 | 2007-09-05 | 默克专利有限公司 | 含有受体酪氨酸激酶抑制剂和血管生成抑制剂的药物组合物及试剂盒 |
RU2363707C2 (ru) * | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Искусственные белки с пониженной иммуногенностью |
US7148321B2 (en) * | 2001-03-07 | 2006-12-12 | Emd Lexigen Research Center Corp. | Expression technology for proteins containing a hybrid isotype antibody moiety |
JP3798285B2 (ja) * | 2001-10-02 | 2006-07-19 | 富士通株式会社 | ネットワークトポロジー収集装置 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7736652B2 (en) | 2002-03-21 | 2010-06-15 | The Regents Of The University Of California | Antibody fusion proteins: effective adjuvants of protein vaccination |
US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20070003514A1 (en) | 2002-04-05 | 2007-01-04 | The Regents Of The University Of California | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination |
IL149820A0 (en) * | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
US20070104710A1 (en) | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
US20040057969A1 (en) | 2002-09-20 | 2004-03-25 | Smith Mark L | Compositions containing stabilized hepatitis antigen and methods of their use |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
JP4790413B2 (ja) | 2002-10-08 | 2011-10-12 | イミューノメディクス、インコーポレイテッド | 抗体療法 |
US7226592B2 (en) | 2002-10-10 | 2007-06-05 | Merck Patent Gmbh | Bispecific anti-Erb-B antibodies and their use in tumor therapy |
ES2729974T3 (es) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Anticuerpo específico de PD-1 y CD3 humanas |
US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
GB0320878D0 (en) | 2003-09-05 | 2003-10-08 | Celltech R&D Ltd | A protein involved in carcinoma |
CA2538141A1 (en) | 2003-09-09 | 2005-03-17 | Gpc Biotech Ag | Therapeutic human anti-mhc class ii antibodies and their uses |
US20050136044A1 (en) * | 2003-12-04 | 2005-06-23 | Watkins Jeffry D. | Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
CA2550551C (en) | 2004-01-16 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
US7247443B2 (en) * | 2004-03-17 | 2007-07-24 | University Of Hawaii | Sensor constructs and detection methods |
ES2387809T3 (es) * | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
KR101201464B1 (ko) | 2004-05-05 | 2012-11-14 | 메리맥 파마슈티컬즈, 인크. | 생물학적 활성을 조정하기 위한 이특이성 결합제 |
AU2005272848A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
AU2005289685B2 (en) | 2004-09-24 | 2009-07-16 | Amgen Inc. | Modified Fc molecules |
US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
AU2005313971B2 (en) | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
CA2595610C (en) | 2004-12-21 | 2013-03-05 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
KR20130105885A (ko) | 2005-01-05 | 2013-09-26 | 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. | 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역 |
TR201901841T4 (tr) | 2005-01-21 | 2019-03-21 | Genentech Inc | Her antikorlarının sabit dozlaması. |
RU2007135216A (ru) | 2005-02-23 | 2009-03-27 | Мерримак Фармасьютикалз, Инк. (Us) | Биспецифические связывающие агенты для модулирования биологической активности |
US20080171067A1 (en) | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
CA2615122A1 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2495257A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007097812A2 (en) * | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
EP1790358A1 (en) | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Protein constructs designed for targeting and lysis of cells |
GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
TW200738750A (en) | 2005-12-06 | 2007-10-16 | Domantis Ltd | Ligands and methods of use therefor |
TW200804425A (en) | 2005-12-06 | 2008-01-16 | Domantis Ltd | Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor |
TW200730191A (en) | 2005-12-15 | 2007-08-16 | Astrazeneca Ab | Combinations |
CA2633486C (en) | 2005-12-16 | 2015-02-03 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US20100266620A1 (en) | 2006-01-20 | 2010-10-21 | Le Sun | Immunoconjugates for treatment of infectious diseases |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
CN101410140B (zh) | 2006-02-02 | 2016-10-26 | 综合医院公司 | 改造抗体-应激蛋白融合物 |
EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
WO2008036449A2 (en) | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Chemical antibodies for immunotherapy and imaging |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
US8350011B2 (en) | 2006-08-04 | 2013-01-08 | Medimmune Limited | Antibodies to ErbB2 |
WO2008032833A1 (fr) | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Anticorps présentant une activité adcc accrue et son procédé de production |
CA2693383C (en) | 2006-10-27 | 2017-03-28 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
US20100166746A1 (en) | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
ES2536900T3 (es) | 2007-02-02 | 2015-05-29 | Baylor Research Institute | Antígenos multivariables en complejo con anticuerpo monoclonal humanizado de dirección |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
BRPI0808418A2 (pt) | 2007-03-02 | 2014-07-22 | Genentech Inc | Predição de resposta a um inibidor de her |
WO2008116293A1 (en) | 2007-03-23 | 2008-10-02 | The Governors Of The University Of Alberta | Multivalent heterobifunctional polymers and methods of their use |
US8263081B2 (en) | 2007-05-14 | 2012-09-11 | The University Of Chicago | Antibody-light fusion products for cancer therapeutics |
KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
ES2614284T3 (es) | 2007-11-30 | 2017-05-30 | Glaxo Group Limited | Construcciones de unión a antígenos |
CA2711256C (en) | 2008-01-03 | 2019-01-15 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US20140127200A1 (en) | 2008-01-03 | 2014-05-08 | The Scripps Research Institute | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains |
CA2712000A1 (en) | 2008-01-28 | 2009-08-06 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
KR20110013409A (ko) | 2008-05-23 | 2011-02-09 | 삼성전자주식회사 | 항체-펩티드 융합 상승체 |
EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US8529943B2 (en) | 2008-07-21 | 2013-09-10 | Compugen Ltd. | Angiopoietin derived peptides |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010066836A2 (en) | 2008-12-10 | 2010-06-17 | Ablynx Nv | Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
EP2432488A4 (en) | 2009-03-20 | 2014-01-08 | Amgen Inc | SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
KR101688522B1 (ko) | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
-
2008
- 2008-12-24 CA CA2711256A patent/CA2711256C/en active Active
- 2008-12-24 CN CN2008801275841A patent/CN101965406A/zh active Pending
- 2008-12-24 US US12/747,883 patent/US20110189206A1/en not_active Abandoned
- 2008-12-24 EA EA201500156A patent/EA201500156A3/ru unknown
- 2008-12-24 WO PCT/US2008/088337 patent/WO2009088805A2/en active Application Filing
- 2008-12-24 CN CN202210664506.7A patent/CN115043946A/zh active Pending
- 2008-12-24 BR BRPI0821906-0A patent/BRPI0821906B1/pt active IP Right Grant
- 2008-12-24 EP EP14154498.1A patent/EP2769991B1/en active Active
- 2008-12-24 GE GEAP200811904A patent/GEP20156390B/en unknown
- 2008-12-24 EA EA201070822A patent/EA021967B1/ru not_active IP Right Cessation
- 2008-12-24 NZ NZ586701A patent/NZ586701A/xx unknown
- 2008-12-24 ES ES14154498.1T patent/ES2689274T3/es active Active
- 2008-12-24 AU AU2008346734A patent/AU2008346734A1/en not_active Abandoned
- 2008-12-24 JP JP2010541504A patent/JP5774851B2/ja active Active
- 2008-12-24 KR KR1020107017256A patent/KR101658247B1/ko active IP Right Grant
- 2008-12-24 DK DK14154498.1T patent/DK2769991T3/en active
- 2008-12-24 SG SG2013026802A patent/SG189769A1/en unknown
- 2008-12-24 EP EP08870383A patent/EP2237797A4/en not_active Withdrawn
- 2008-12-24 CN CN201810794874.7A patent/CN108864285A/zh active Pending
- 2008-12-24 SG SG10201605629VA patent/SG10201605629VA/en unknown
- 2008-12-24 MX MX2010007357A patent/MX2010007357A/es not_active Application Discontinuation
-
2010
- 2010-06-24 IL IL206602A patent/IL206602A0/en unknown
- 2010-07-05 ZA ZA2010/04730A patent/ZA201004730B/en unknown
-
2012
- 2012-11-01 US US13/694,155 patent/US20130195860A1/en not_active Abandoned
- 2012-12-16 IL IL223647A patent/IL223647A0/en unknown
-
2015
- 2015-07-02 JP JP2015133213A patent/JP2015227345A/ja active Pending
- 2015-12-09 US US14/963,722 patent/US10030051B2/en active Active
-
2016
- 2016-11-10 IL IL248905A patent/IL248905A0/en active IP Right Grant
-
2017
- 2017-09-29 JP JP2017190339A patent/JP2018015002A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060128944A1 (en) * | 2001-08-21 | 2006-06-15 | Yeda Research And Development Co. Ltd. At The Weizmann Instritute Of Science | Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors |
US20030229023A1 (en) * | 2001-10-11 | 2003-12-11 | Oliner Jonathan Daniel | Specific binding agents of human angiopoietin-2 |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20070254316A1 (en) * | 2002-08-05 | 2007-11-01 | Johns Hopkins University | Peptides for targeting the prostate specific membrane antigen |
US20070202041A1 (en) * | 2006-02-24 | 2007-08-30 | Arius Research, Inc. | Cancerous disease modifying antibodies |
Non-Patent Citations (6)
Title |
---|
CORTE-REAL et al.: "Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells", Blood, 5 December 2005 (05.12.2005), vol. 106, No 12, pages 3797-3802, pg. 3798, para 4 * |
GRZESIK et al.: "Synthetic integrin-binding peptides promote adhesion and proliferation of human periodontal ligament cells in vitro", J. Dent. Res., August 1998 (08.1998), vol. 77, No 8, pages 1606-1612, abstract * |
KUTTY et al.: "Identification of a New Member of Transforming Growth Factor-Beta Superfamily in Drosophila The First Invertebrate Activin Gene", Biochem. Biophys. Res. Commun., 1998, vol. 246, pg. 644-649, Especially Fig. 1 * |
NIU et al.: "Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways", Cancer Res., 15 February 2007 (15.02.2007), vol. 67, No 4, pages 1487-1493, abstract * |
RUOSLAHTI, E.: "Integrins", J. Clin. Invest., January 1991, vol. 87, pg. 1-5. Entire document, especially pg. 1, col. 1, para 3 * |
TAIPALE et al.: "Growth factors in the extracellular matrix", FASEB J., January 1997, vol. 11, pg. 51-59, entire document, especially pg. 51, col. 2, para 1, pg. 56, col. 2, para 6, pg. 54, col. 2, para 4 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA021967B1 (ru) | Доставка антител посредством модульного домена распознавания | |
KR102636776B1 (ko) | 결합능을 갖는 융합 단백질을 포함하는 세포외 소포 | |
ES2764111T3 (es) | Anticuerpos multiespecíficos | |
Kontermann | Dual targeting strategies with bispecific antibodies | |
RU2096459C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ (Fab)2 - ФРАГМЕНТОВ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ | |
US20240052063A1 (en) | Binding Proteins 2 | |
Kazane et al. | Self-assembled antibody multimers through peptide nucleic acid conjugation | |
TWI614264B (zh) | 含胜肽核的多臂接合物及其應用 | |
RU2355705C2 (ru) | Одноцепочечное цикличное триспецифическое антитело | |
JP2019077731A (ja) | 改変した抗体組成物、それを作製および使用する方法 | |
JP2021502810A5 (ru) | ||
ES2659406T3 (es) | Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6) | |
CN111499753B (zh) | 双功能抗体及其用途 | |
JP2008535475A5 (ru) | ||
JP2012511033A (ja) | 多価化合物の可逆阻害用マスキングリガンド | |
JPWO2021119516A5 (ru) | ||
JP2015512247A5 (ru) | ||
US11040111B2 (en) | Bi-specific antibodies and uses thereof | |
US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
Lim | Fine-tuning bispecific therapeutics | |
KR20050036873A (ko) | 친화력 증강제 | |
JP7206297B2 (ja) | 大核酸の細胞内標的指向送達 | |
Kujawski et al. | T‐cell surface generation of dual bivalent, bispecific T‐cell engaging, RNA duplex cross‐linked antibodies (dbBiTERs) for re‐directed tumor cell lysis | |
JP2020532543A (ja) | 抗egfr抗体薬物コンジュゲート(adc)及びその使用 | |
US11952402B2 (en) | Fusion protein containing trail and IgG binding domain and the uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |